|
Levothyroxine (Thyroxine) Oral
|
| bet | 590/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Levothyroxine (Thyroxine) Oral
Revision Date : 26-2-2021
|
Approved: TC, KOH
|
Alert
|
Levothyroxine sodium is the International Nonproprietary Name for thyroxine sodium.
Three different brands are available: Eutroxsig, Oroxine and Eltroxin.
Eltroxin is not bioequivalent on a same dose basis with Eutroxsig or Oroxine.
Prescribers should not to interchange Eltroxin and Eutroxsig or Oroxine unless a decision has been made to switch products and there is a plan for monitoring TSH levels and review of dose. The patient should be informed of the same.[1, 2]
|
Indication
|
Thyroid hormone deficiency
|
Action
|
Levothyroxine exerts effects on most organ systems and is particularly important in the development of the central nervous system. Increases the metabolic rate of body tissues. Also involved in the regulation of cell growth and differentiation.
|
Drug Type
|
Levothyroxine sodium previously known as thyroxine sodium, is the monosodium salt of the levo- isomer of thyroxine, the principal secretion of the thyroid gland
|
Trade Name
|
Eltroxin tablets, Eutroxsig tablets, Oroxine tablets.
|
Presentation
|
Eutroxsig and Oroxine tablets: 50 microgram, 75 microgram, 100 microgram, 200 microgram tablets
Eltroxin tablets: 25 microgram, 50 microgram, 75 microgram, 100 microgram, 125 microgram, 200 microgram tablets.
|
|
|
| |
